Vijaya Diagnostic Centre Ltd

Q2 FY26Healthcare Services

Vijaya Diagnostic Centre Q2 FY26: Capex ₹160 Cr

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,504

Market cap₹14.3K Cr

P/E82.7

Updated23 Aug 2026

Read5 min read

The short version

Vijaya Diagnostic Centre targets around 15% overall year-level growth. Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this. - EBITDA margins are expected to be around 40% for FY27, slightly improving as new centers break even. - CAPEX for FY27 is anticipated between Rs.100 to Rs.120 crores, lower than FY26’s Rs.160 crores, supporting margin expansion. - Break-even for new hubs is targeted within one year, with some new centers achieving earlier break-even. - Growth is expected to be volume-driven across new geographies (Bangalore, Kolkata, Pune) for the next 1–1.5 years, with limited price hikes unless input costs necessitate. - The company remains confident about surpassing current EBITDA margin guidance, having delivered ~39.2% in recent quarters vs.

From Vijaya Diagnostic Centre Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Vijaya Diagnostic Centre targets around 15% overall year-level growth.
Radiology volume growth guidance is around 13%, with realization growth of 1.5-2%.
Growth is volume-driven across new geographies (Bangalore, Kolkata, Pune), especially in initial 1-1.5 years, with limited price hikes expected near-term.
Multiple new hubs and spokes expected to be operational, increasing volume and contribution from advanced radiology.
Bangalore hubs expected to grow by volume for 1-1.5 years; some hubs have broken even earlier.
Pune hubs expected to break even within about a year; some cleanup activities delayed ramp-up.
Despite seasonality and weather factors impacting pathology volumes temporarily, the company is optimistic on steady normalized growth.

2 more points management made on revenue & sales performance

Profitability & Margins

Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this.
EBITDA margins are expected to be around 40% for FY27, slightly improving as new centers break even.
CAPEX for FY27 is anticipated between Rs.100 to Rs.120 crores, lower than FY26’s Rs.160 crores, supporting margin expansion.
Break-even for new hubs is targeted within one year, with some new centers achieving earlier break-even.
Growth is expected to be volume-driven across new geographies (Bangalore, Kolkata, Pune) for the next 1–1.5 years, with limited price hikes unless input costs necessitate.

2 more points management made on profitability & margins

See what Vijaya Diagnostic Centre Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

FY26 CAPEX for new centres is about Rs.160 crores, majority incurred by H1FY26.
FY27 CAPEX expected between Rs.100 to Rs.120 crores, lower than FY26.
CAPEX focused on opening new hubs and spokes in various geographies including Bangalore, Kolkata, Pune, and core markets.
Two hubs opened recently in Nandyal and Khammam; two more hubs planned in Q3 FY26.
Plans to increase hubs from current two to five by end of FY27.
Long-term expansion plan includes lease properties for new hubs/spokes.

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There is no mention of any current or planned fundraising through debt or equity in the transcript.
The company reported having a surplus cash balance of around Rs. 235 crores as of September 30, 2025, indicating a strong liquidity position.
Discussions around capital expenditure indicate internal funding plans (Rs.160 crores CAPEX for FY26 and Rs.100-120 crores for FY27), without reference to external fundraising.

2 more points management made on fundraising & capital structure

See what Vijaya Diagnostic Centre Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript from Vijaya Diagnostic Centre Limited's earnings call on November 4, 2025, does not explicitly mention a current or expected order book or pending orders. However, relevant insights include: - The company is actively expanding through opening new hubs and spokes across various cities like Bangalore, Pune, Kolkata, and Hyderabad. - They plan to add 4-5 hubs and 10-12 spokes by the end of FY26. - CAPEX for H2FY26 stands at Rs.160 crores (mostly incurred in H1), with an expected Rs.100-120 crores CAPEX planned for FY27. - Focus is on stabilizing new centers before further expansion, especially in Pune.

2 more points management made on order book & pipeline

Vijaya Diagnostic Centre Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹219 Cr, net profit ₹48 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Vijaya Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

3B Blackbio DX Ltd (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
Unihealth Hospitals Ltd (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Indegene (Q2 FY26)
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…
Dr Lal Pathlabs Ltd (Q2 FY26)
Sustained 11%-12% revenue growth without price hikes is planned, driven by increased patient volume and revenue per patient. Key concall takeaways from Dr Lal…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Vijaya Diagnostic Centre Ltd Q2 FY26 results?

What is Vijaya Diagnostic Centre Ltd share price analysis?

Vijaya Diagnostic Centre Ltd currently shows a neutral. The stock trades at a P/E of 82.7 with a market cap of ₹14,313 Cr. Investors should review the full earnings analysis for detailed insights.

Is Vijaya Diagnostic Centre Ltd planning capital expenditure?

FY26 CAPEX for new centres is about Rs.160 crores, majority incurred by H1FY26.

Keep Vijaya Diagnostic Centre Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.